S. Senger

Evaluation of EGFR gene copy number as a predictive biomarker for the efficacy of cetuximab in combination with chemotherapy in the first-line treatment of recurrent and/or metastatic squamous cell carcinoma of the head and neck: EXTREME study

S. Störkel, M. Benasso, C. Stroh, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Pharmacogenomic and pharmacoproteomic studies of cetuximab in metastatic colorectal cancer: biomarker analysis of a phase I dose-escalation study.

F. J. Ramos, J. Baselga, F. Rojo, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized Phase II Study of BLP25 Liposome Vaccine (L-BLP25) in Patients with Multiple Myeloma

A. Österborg, A. Choudhury, H. Mellstedt, 2011 .

Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study.

M. Nishio, N. Yamamoto, T. Tamura, 2011, Japanese journal of clinical oncology.

Cetuximab Plus irinotecan in pretreated metastatic colorectal cancer progressing on irinotecan: the LABEL study.

A. Buzaid, L. Fein, G. Lerzo, 2010, Clinical colorectal cancer.

L-BLP25 for unresectable stage III non-small cell lung cancer after primary chemoradiotherapy in Japanese patients: Preliminary safety results from a phase I/II study.

M. Nishio, N. Yamamoto, T. Tamura, 2010 .